Abstract
Systemic exposure of a drug is generally associated with its pharmacodynamic (PD) effect (e.g., efficacy and toxicity). In this regard, the change in area under the plasma concentration-time curve (AUC) of a drug, representing its systemic exposure, has been mainly considered in evaluation of drug-drug interactions (DDIs). Besides the systemic exposure, the drug concentration in the tissues has emerged as a factor to alter the PD effects. In this review, the status of systemic exposure, and/or tissue exposure changes in DDIs, were discussed based on the recent reports dealing with transporters and/or metabolic enzymes mediating DDIs. Particularly, the tissue concentration in the intestine, liver and kidney were referred to as important factors of PK-based DDIs.
| Original language | English |
|---|---|
| Article number | 417 |
| Journal | Pharmaceutics |
| Volume | 12 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2020 |
Keywords
- Drug interaction
- Pharmacokinetics
- Systemic exposure
- Tissue-specific